Predictors of Incident Mild Cognitive Impairment and Its Course in a Diverse Community-Based Population

Milou J Angevaare1, Jet M J Vonk1, Laiss Bertola1

  • 1From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain (M.J.A., J.M.J.V., L.B., L.Z., C.W.-M.W., A.B., N.S., R.M., J.J.M.), College of Physicians and Surgeons, Columbia University, New York, NY; Julius Center for Health Sciences and Primary Care (M.J.A., J.M.J.V., M.I.G.), University Medical Center Utrecht; Amsterdam UMC (M.J.A.), Vrije Universiteit Amsterdam, Department of Medicine for Older People, Amsterdam Public Health Research Institute, Van der Boechorststraat 7, the Netherlands; and National Institute of Science and Technology in Molecular Medicine (L.B.), Federal University of Minas Gerais, Belo Horizonte, Brazil.

Neurology
|December 2, 2021
PubMed
Abstract

Insights

Nearly half of individuals diagnosed with mild cognitive impairment (MCI) reverted to cognitively normal. Predictors for MCI incidence differ from those influencing its subsequent course, impacting dementia progression.

Area of Science:

  • Neuroscience
  • Gerontology
  • Epidemiology

Background:

  • Mild cognitive impairment (MCI) is a transitional stage between normal cognition and dementia.
  • Understanding predictors of MCI incidence and its course is crucial for early intervention and prognosis.

Purpose of the Study:

  • To identify sociodemographic and medical factors predicting incident MCI.
  • To examine predictors of MCI outcomes, including sustained MCI, cognitive recovery, and dementia progression.

Main Methods:

  • A community-based cohort study with 2,903 initially cognitively normal participants.
  • MCI diagnosed using a published algorithm; dementia diagnosed by clinical consensus.
  • Cox and modified Poisson regressions analyzed predictors of MCI incidence and follow-up status.

Main Results:

  • 752 participants developed MCI (incidence rate 56/1,000 person-years).
  • APOE ε4 and higher medical burden predicted MCI incidence; education, leisure, and income were protective.
  • Of MCI cases, 12.9% progressed to dementia; multidomain MCI, APOE ε4, depression, and antidepressant use increased dementia risk.

Conclusions:

  • Nearly half of incident MCI cases reverted to normal cognition, highlighting the dynamic nature of MCI.
  • Distinct predictors influence MCI onset versus its subsequent course, informing prognostic expectations and management strategies.

Related Concept Videos

Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
364
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
735
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
213
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
290
Community Based Intervention01:30

Community Based Intervention

Community-based interventions in mental health represent a paradigm shift from institution-centered care to treatments embedded within the fabric of local communities. By prioritizing inclusion and leveraging existing societal structures, this approach fosters a supportive environment conducive to addressing mental health challenges while promoting individual dignity and agency.
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
110